De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Emergent BioSolutions Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Joe Papa

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	1.7yrs
Gemiddelde ambtstermijn bestuur	3.3yrs

Recente managementupdates

Recent updates

Little Excitement Around Emergent BioSolutions Inc.'s (NYSE:EBS) Revenues As Shares Take 27% Pounding

Sep 16

Emergent BioSolutions: Speculative Buy Amid Potential Monkeypox Vaccine Approval

Aug 18

Emergent BioSolutions Inc. (NYSE:EBS) Held Back By Insufficient Growth Even After Shares Climb 41%

Aug 02

An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 30% Undervalued

Jun 22

Is Emergent BioSolutions (NYSE:EBS) Using Too Much Debt?

Apr 05

Emergent Biosolutions Q4 2022 Earnings Preview

Feb 24

An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 39% Undervalued

Feb 16

Emergent BioSolutions to offload travel health business to Bavarian Nordic for $380M

Feb 15

Emergent BioSolutions: No Change To Thesis Following Latest Numbers, Recent Developments

Dec 07

Emergent plunges 30% on quarterly earnings miss, lowers full-year guidance

Nov 09

Emergent doses first participant in Phase 1 trial for Lassa virus vaccine

Sep 06

Emergent BioSolutions: Now Long Through Sale Of October Put Spreads

Aug 24

CEO

Joe Papa (68 yo)

less than a year

Tenure

Mr. Joseph C. Papa, Jr. also known as Joe, is Director of Milestone Pharmaceuticals Inc. since September 3, 2024. Mr. Papa serves as Executive Advisor at Water Street Healthcare Partners, LLC since joining...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Richard Lindahl	Executive VP	6.6yrs	US$2.18m	0.29% $ 1.4m
Coleen Glessner	Executive Vice President of Global Quality and Ethics & Compliance	2.5yrs	US$1.68m	0.30% $ 1.5m
Paul Williams	Senior Vice President of Products Business	1.8yrs	US$1.06m	0.045% $ 223.6k
Joseph Papa	CEO, President & Director	less than a year	geen gegevens	geen gegevens
Jessica Perl	Corporate Secretary and Interim General Counsel	less than a year	geen gegevens	geen gegevens
Michelle Pepin	Senior VP & Chief Human Resource Officer	1.6yrs	geen gegevens	geen gegevens
Stephanie Duatschek	Senior VP	1.6yrs	geen gegevens	geen gegevens
Kelly Warfield	Senior VP of Science & Development	1.8yrs	geen gegevens	geen gegevens
William Hartzel	Senior Vice President of Manufacturing & Bioservices	no data	geen gegevens	0.089% $ 442.1k

1.7yrs

Gemiddelde duur

58.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van EBS wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.7 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Joseph Papa	CEO, President & Director	less than a year	geen gegevens	geen gegevens
Louis Sullivan	Independent Director	18.3yrs	US$400.23k	0.099% $ 490.9k
Ronald Richard	Independent Director	19.8yrs	US$394.73k	0.037% $ 182.3k
Donald DeGolyer	Independent Director	less than a year	US$397.50k	geen gegevens
Keith Katkin	Independent Director	2.5yrs	US$396.99k	0.011% $ 52.7k
Marvin White	Independent Director	4yrs	US$405.98k	0.032% $ 157.2k
Zsolt Harsanyi	Independent Non-Executive Chairman	20.2yrs	US$535.98k	0.070% $ 349.7k
Kathryn Zoon	Independent Director	7.9yrs	US$413.48k	0.069% $ 340.5k
Neal Fowler	Independent Director	less than a year	US$398.75k	geen gegevens
Sujata Dayal	Independent Director	2.3yrs	US$382.23k	0.0073% $ 36.3k

3.3yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van EBS wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Emergent BioSolutions Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

High number of new directors

Emergent BioSolutions Inc., Annual General Meeting, May 23, 2024

High number of new directors

Emergent BioSolutions Inc. Announces Changes in CEO

Emergent Biosolutions Inc. Announces Board Appointments

Emergent BioSolutions Inc. Announces Demise of Jerome Hauer, Ph.D., Director

Recent updates

Consensus estimates of losses per share improve by 14%

Little Excitement Around Emergent BioSolutions Inc.'s (NYSE:EBS) Revenues As Shares Take 27% Pounding

Emergent BioSolutions’ ACAM2000, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions

Emergent BioSolutions: Speculative Buy Amid Potential Monkeypox Vaccine Approval

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Emergent BioSolutions Inc. Updates Earnings Guidance for the Full Year of 2024

Emergent BioSolutions Inc. (NYSE:EBS) Held Back By Insufficient Growth Even After Shares Climb 41%

High number of new directors

Emergent BioSolutions Inc. to Report Q2, 2024 Results on Aug 06, 2024

Emergent BioSolutions: A Much-Needed Mid-Stage Turnaround In Process

Emergent BioSolutions Inc.(NYSE:EBS) dropped from Russell 3000 Index

Emergent BioSolutions: High-Risk, High-Reward Strategic Turnaround

Emergent BioSolutions Inc. Revises Earnings Guidance for the Year 2024

Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position

Emergent BioSolutions Inc. to Report Q1, 2024 Results on May 01, 2024

New minor risk - Market cap size

Emergent BioSolutions Inc., Annual General Meeting, May 23, 2024

High number of new directors

Emergent Biosolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility

Full year 2023 earnings: EPS misses analyst expectations

Emergent BioSolutions Inc. Provides Revenue Guidance for the First Quarter and Earnings Guidance for the Full Year of 2024

Emergent BioSolutions Inc. to Report Q4, 2023 Results on Mar 06, 2024

New CEO Appointment A Clear Positive For Emergent BioSolutions

New major risk - Share price stability

Emergent BioSolutions Inc. Announces Changes in CEO

Emergent BioSolutions: Q3 Numbers Leave Work To Be Done

Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing

Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing

Emergent BioSolutions: Meaningful Debt, But Narcan Should Grow

Emergent BioSolutions Inc. announced delayed 10-Q filing

Emergent BioSolutions Inc. Updates Earnings Guidance for the Year 2023

Price target decreased by 55% to US$5.00

Emergent BioSolutions Inc. to Report Q3, 2023 Results on Nov 02, 2023

Emergent Biosolutions Inc. Announces Board Appointments

Emergent Biosolutions' Narcan®? Nasal Spray Launches over the Counter Making It Possible for Everyone to Help Save A Life from an Opioid Overdose Emergency

Emergent BioSolutions Is Clearly Risky, But The Reward Could Be Substantial

Emergent BioSolutions Inc. Announces Demise of Jerome Hauer, Ph.D., Director

Financial Woes Darken Emergent BioSolutions' Outlook (Rating Downgrade)

Emergent BioSolutions Inc. Reports Impairment of Long-Lived Assets for the Second Quarter Ended June 30, 2023

Emergent BioSolutions Inc. Announces Executive Changes

Emergent BioSolutions Inc. to Report Q2, 2023 Results on Aug 08, 2023

Emergent BioSolutions Inc. Receives U.S. FDA Approval of CYFENDUS ( Anthrax Vaccine Adsorbed, Adjuvanted), A Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

Emergent BioSolutions: Making A Big Bet On Narcan

Emergent BioSolutions Inc. Announces Resignation of Robert G. Kramer Sr. as President and Member of the Company's Board

Emergent BioSolutions Inc.(NYSE:EBS) dropped from Russell 2000 Value-Defensive Index

An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 30% Undervalued

Consensus EPS estimates fall by 35%, revenue upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Emergent Biosolutions Inc. Revises Earnings Guidance for the Full Year of 2023

Consensus EPS estimates upgraded to US$1.85 loss

Is Emergent BioSolutions (NYSE:EBS) Using Too Much Debt?

Consensus EPS estimates fall by 79%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Emergent Biosolutions Q4 2022 Earnings Preview

Emergent BioSolutions Inc. Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use

An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 39% Undervalued

Investor sentiment improves as stock rises 15%

Emergent BioSolutions to offload travel health business to Bavarian Nordic for $380M

Emergent BioSolutions Inc. to Report Q4, 2022 Results on Feb 27, 2023

Emergent Biosolutions Inc. Announces Executive Changes

Emergent BioSolutions Inc. Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-The-Counter NARCAN® (Naloxone HCI) Nasal Spray

Emergent BioSolutions: No Change To Thesis Following Latest Numbers, Recent Developments

Consensus EPS estimates fall by 283%

Price target decreased to US$36.80

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Emergent plunges 30% on quarterly earnings miss, lowers full-year guidance

Emergent BioSolutions Inc. Revises Earnings Guidance for the Year 2022

Emergent BioSolutions Inc. Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines

Consensus forecasts updated